Advanced Biosciences Laboratories, PATH Partner in Vaccine Production
Advanced Biosciences Laboratories will support the development and production of a novel Shigella vaccine candidate for PATH.
Advanced BioScience Laboratories, Inc. (ABL), a biomedical contract research and manufacturing organization, has been selected by PATH, an international nonprofit global health organization, to support the development and production of a novel Shigella vaccine candidate. ABL will develop a scalable GMP production process to produce toxicology and Phase I clinical supply at its facility located in Rockville, Maryland.
The vaccine candidate is based on IpaB/IpaD fusion protein technology developed in the laboratory of Wendy Picking, associate professor in the Department of Microbiology and Molecular Genetics at Oklahoma State University. The IpaB and IpaD proteins are highly conserved within Shigella species and, therefore, are expected to stimulate broad protective immune responses against multiple serotypes, according to ABL.
Source: ABL
